Literature DB >> 26927008

Cardiovascular Complications of Novel Multiple Myeloma Treatments.

Weijuan Li1, R Frank Cornell1, Daniel Lenihan1, David Slosky1, Madan Jagasia1, Gregory Piazza2, Javid Moslehi1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26927008     DOI： 10.1161/CIRCULATIONAHA.115.018351

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  11 in total

Review 1.  Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.

Authors:  Vivek G Patel; Robert F Cornell
Journal:  Curr Oncol Rep       Date:  2019-03-05       Impact factor: 5.075

Review 2.  Cardio-oncology: A Focus on Cardiotoxicity.

Authors:  Athanasios Koutsoukis; Argyrios Ntalianis; Evangelos Repasos; Efsthathios Kastritis; Meletios-Athanasios Dimopoulos; Ioannis Paraskevaidis
Journal:  Eur Cardiol       Date:  2018-08

Review 3.  Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention.

Authors:  Dae Hyun Lee; Michael G Fradley
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-06

Review 4.  Arterial Thrombosis in Patients with Cancer.

Authors:  Mirela Tuzovic; Joerg Herrmann; Cezar Iliescu; Kostas Marmagkiolis; Boback Ziaeian; Eric H Yang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-07

Review 5.  Cardiotoxicity of Novel Targeted Hematological Therapies.

Authors:  Valentina Giudice; Carmine Vecchione; Carmine Selleri
Journal:  Life (Basel)       Date:  2020-12-11

6.  Bortezomib-Induced Reversible Cardiomyopathy: Recovered With Guideline-Directed Medical Therapy.

Authors:  Swethika H Sundaravel; Rosalyn I Marar; Muhannad A Abbasi; Muhamed Baljevic; Jeremy R Stone
Journal:  Cureus       Date:  2021-12-09

Review 7.  Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Authors:  Ping-Pin Zheng; Jin Li; Johan M Kros
Journal:  Med Res Rev       Date:  2017-09-01       Impact factor: 12.944

8.  Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma.

Authors:  Eric H Yang; Cynthia Courtney; Vinisha Garg; Michael G Fradley; Gary J Schiller
Journal:  Cardiooncology       Date:  2018-03-01

Review 9.  Hematological Malignancies and Arterial Thromboembolism.

Authors:  Nathan Visweshwar; Michael Jaglal; Lubomir Sokol; Benjamin Djulbegovic
Journal:  Indian J Hematol Blood Transfus       Date:  2019-01-28       Impact factor: 0.900

10.  Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma.

Authors:  Deborah Osafehinti; Kaveh Zivari
Journal:  Case Rep Hematol       Date:  2019-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.